Osseor Articles
Benefits of Diane 35 and generics outweigh risks in specific patient group, says EMA unit; other actions
17 May 2013
EMA backs Protelos and Osseor, but with warnings
19 March 2012
Showing 1-3 of 3 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
